Introduction
Coenzyme Q 10 (CoQ) is a lipophilic molecule that is involved in the mitochondrial ATP synthesis because of its function as an electron between mitochondrial complexes I and II, as well as ETF:Q oxidoreductase, and mitochondrial complex III [1] . Moreover, CoQ 10 functions as an antioxidant, which protects the cells both directly by preventing the oxidation of biomolecules and indirectly by regenerating other antioxidants such as vitamins C and E [1] . Due to these properties, oral supplementation with CoQ 10 (in its stable oxidized form, ubiquinone-10) has been proposed for the treatment of diseases involving mitochondrial dysfunction and/ or oxidative stress, i.e. primary mitochondrial disorders, Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease or heart failure [2] [3] [4] [5] [6] . Moreover, oral ubiquinone-10 supplementation is the main choice in the treatment of primary (MIM 607426) and secondary CoQ 10 deficiencies [7] .
Despite the good expectation that ubiquinone-10 therapy has presented, the studies in different diseases, both at preclinical and clinical levels, have shown contradictory results. Specially, ubiquinone-10 seems to be less effective in improving the neurological symptoms and, in some cases, higher doses are needed to appreciate some clinical improvement [7] . The mild or completely lack of response to ubiquinone-10 therapy has been attributed to its low absorption and bioavailability that limit the increase of CoQ 10 in cell mitochondria, where it is biologically active [8] . This limitation is even more important in the brain because the exogenous ubiquinone-10 must be able to cross the blood brain barrier. Thus, different strategies have been investigated to increase the absorption and bioavailability of the exogenous CoQ 10 . In this regard, water-soluble formulations of ubiquinone-10 seem to increase its bioavailability. Different studies have shown that concentration of CoQ 10 in plasma after administration of water-soluble formulations of ubiquinone-10 is higher than that after supplementation with ubiquinone-10 administered as powder water-insoluble formulations [8] . Moreover, the plasma levels of CoQ 10 are also higher when CoQ 10 is administered as ubiquinol-10, the reduced form of CoQ 10 , than when it is administered as ubiquinone-10 [8] .
To evaluate whether water soluble formulations of ubiquinone-10, as well as the use of the reduced form, ubiquinol-10, may increase the efficacy of CoQ 10 therapy in the nervous system, in this study we have used water-soluble formulations of ubiquinone-10 and ubiquinol-10 to treat a mouse model of mitochondrial encephalopathy and CoQ deficiency due to Coq9 mutations (Coq9
Materials and methods

Mice use and experimental treatment
Generation and characterization of Coq9 X/X mice (C57BL/6 genetic background) were previously reported [9] . ). Mice were housed in the Animal Facility of the University of Granada under a specific pathogen free zone with lights on at 7:00 AM and off at 7:00 PM, and with unlimited access to water and rodent chow. Mice were sacrificed using CO 2 narcosis followed by cervical dislocation at 3 months of age. The treatment consisted of administering ubiquinone-10 or ubiquinol-10 in the drinking water in a dose of 240 mg/kg bw/day. The treatment started at 1 month of age and the mice were sacrificed at 3 months of age. Ubiquinone-10 and ubiquinol-10 were provided by Kaneka Corporation (Japan) in a water-soluble formulation that contains dextrin, Arabic gum and ascorbic acid. A control group with vehicle at the same dose was also studied. The drinking water was changed twice a week.
Mitochondrial isolation
Cerebrum was homogenized in a glass-Teflon homogenizer in a proportion 1:5, w/v, in the homogenization medium A (0.32 M sucrose, 1 mM EDTA, 10 mM Tris-HCl [pH 7.4]) plus 0.2% fatty acid-free bovine serum albumin. Homogenate was centrifuged at 1000 g for 5 min at 4°C to remove nuclei and debris. Mitochondria were collected from supernatants after centrifuging at 14,400 g for 2 min at 4°C. The mitochondrial pellet was suspended in the corresponding buffer and an aliquot of each sample was used for protein determination [9] . 9 and CoQ 10 levels in plasma, mice tissues and cerebrum mitochondria CoQ 9 and CoQ 10 from mice tissues were extracted by mixing tissue extracts with 1-propanol. After 2 min vortex, the solution was centrifuged at 11,300 g for 5 min. The resultant supernatant contained the lipid extract [9] . CoQ 9 and CoQ 10 from plasma and cerebrum mitochondria were extracted in a hexane:ethanol mixture [10] . The lipid extract was injected in a HPLC system (Gilson, WI, USA) and the lipid components were separated by a reverse phase Symmetry C18 3.5 μm, 4.6 × 150 mm column (Waters, Spain), using a mobile phase consisting of methanol, ethanol, 2-propanol, acetic acid (500:500:15:15) and 50 mM sodium acetate at a flow rate of 0.9 ml/min. The electrochemical detector consisted of an ESA Coulochem III with the following setting: guard cell (upstream of the injector) at +900 mV, conditioning cell at −600 mV (downstream of the column), followed by the analytical cell at +350 mV [9] . CoQ 9 and CoQ 10 concentrations were estimated by comparison of the peak areas with those of standard solutions of known concentrations. The results were expressed in ng CoQ/mg prot.
Quantification of CoQ
CoQ-dependent respiratory chain activities
CoQ dependent respiratory chain activities were measured in submitochondrial particles. To prepare submitochondrial particles, each mitochondrial pellet (100 μg prots) was suspended and sonicated in 100 μl of 0.1 M potassium phosphate buffer, pH 7.5. Complex I + III activity was measured at 30°C in the presence of 0.5 mM potassium cyanide, 0.2 mM NADH and 0.1 mM cytochrome c, as the rotenone-sensitive reduction of cytochrome c at 550 nm [9, 11] . The results were expressed in nmol reduced cyt c/min/mg prot. Complex II + III activity was measured at 30°C in the presence of 0.5 mM KCN, 0.3 mM succinate and 0.01 mM rotenone. The reaction was initiated by addition of 0.1 mM cytochrome c and decrease in absorbance was monitored at 550 nm. The results were expressed in nmol reduced cyt c/min/mg prot [11] .
2.5. Blue native gel electrophoresis and immunoblotting for the evaluation of mitochondrial supercomplex pattern Blue native gel electrophoresis (BNGE) was performed on mitochondrial fraction from cerebrum. The mitochondrial pellets were suspended in 140 μl in the homogenization medium A. An aliquot of each sample was used for protein determination. The remaining samples were then centrifuged at 17,000 g for 3 min at 4°C. Mitochondrial pellets were suspended in an appropriate volume of buffer B (1 M 6-amiohexanoic acid, 50 mM Bis-Tris-HCl [pH 7.0]) to be at 10 mg/ml, and the membrane proteins were solubilized by the addition of digitonin (4 g/g) and incubated for 5 min in ice. After 30 min centrifugation at 13,000 g, the supernatant was collected, and 3 μl of 5% Brilliant Blue G dye prepared in 1 M 6-amiohexanoic acid was added [9] . Mitochondrial proteins (100 μg) were then applied and ran on a 3%-13% gradient native gel using electrophoresis system mini-PROTEAN Tetra Cell (Bio-rad). Western blot was performed using a mini Trans-blot Cell onto PVDF membranes and probes with specific antibodies against complex I, anti-NUDFA9 (Abcam, ab14713), complex III, anti-ubiquinol-cytochrome c reductase Core Protein I (Abcam, ab110252) and Vdac1 (Abcam, ab14734) [9, 12] .
Mitochondrial complex I in-gel catalytic activity assay
Mitochondrial membrane proteins (100 μg) were applied and ran on a 3%-13% first-dimension gradient BNGE gel as described elsewhere [13] . The assay buffer contained 10 mg of NTB and 0.14 mM NADH added to 10 ml of 100 mM Tris/HCl, pH 7.4. After about 30 min the reaction was stopped using 5 mM Tris/HCl, pH 7.4 and scanned for densitometric quantitation.
Histology and Immunohistochemistry
Mice tissues were formalin-fixed and paraffin-embedded. Multiple sections (4 μm thickness) were deparaffinized with xylene and stained with hematoxylin and eosin (H&E). Immunohistochemistry was carried out in the same sections, using the following primary antibodies: antiglial fibrillary acidic protein (GFAP) (Millipore, MAB360), anti-Neuronal Class III β-tubulin (TUJ1) (Covance, MMS-435P) and anti-8-hydroxy-2′-deoxyguanosine (8-OHdG) (QED Bioscience, 12501). Dako Animal Research Kit for mouse primary antibodies (Dako Diagnóstico S.A., Spain) was used for the qualitative identification of antigens by light microscopy. Sections were examined at 40-400 magnifications with an OLYMPUS CX41 microscope, and the images were scanned under equal light conditions with the CELL A computer program [9] .
Statistical analysis
All statistical analyses were performed using the GraphPad scientific software. Data are expressed as the mean ± SD of seven-ten experiments per group. A one-way ANOVA with a Tukey post hoc test was used to compare the differences between groups. A P-value of 0.05 was considered to be statistically significant.
Results
CoQ 10 levels in plasma and tissues of Coq9
X/X after 2 months of treatment
We previously reported that Coq9 X/X mice showed a significant decrease in both CoQ 9 (the major form of ubiquinone in rodents) and CoQ 10 levels at 3 months of age compared with the age-mated Coq9 +/+ mice in all examined tissues (cerebrum, cerebellum, heart, kidney, hind legs skeletal muscle and liver) [9] . Two months of ubiquinone-10 or ubiquinol-10 therapies increased plasma levels of CoQ 10 in Coq9 X/X mice, while levels of CoQ 9 did not change in the same animals (Table 1) . Treatment with vehicle did not produce any effects in the plasma CoQ 10 levels. In tissues, a significant increase of CoQ 10 after ubiquinone-10 treatment was only detected in liver and muscle. On the contrary, CoQ 10 levels were significantly increased in the cerebrum, cerebellum, heart, kidney, liver and hind leg skeletal muscle of Coq9 X/X mice treated with ubiquinol-10 ( Fig. 1) . The increase of CoQ 10 levels after ubiquinone-10 or ubiquinol-10 treatments was in parallel to a decrease in the CoQ 9 /CoQ 10 ratio (Fig. S1 ), which indicates that these therapies did not affect the CoQ 9 levels (Fig. S2) . Compared to the vehicle group, the highest increase of CoQ 10 after ubiquinone-10 or ubiquinol-10 treatments was found in liver and muscle, followed by heart, kidney, cerebrum and cerebellum. Only muscle and heart of Coq9 X/X mice treated with ubiquinol-10 reached similar CoQ 10 levels than that of Coq9 +/+ mice, while liver accumulated huge amounts of CoQ 10 after ubiquinone-10 or ubiquinol-10 treatment (Fig. 1). 3.2. CoQ levels in cerebral mitochondria of Coq9 X/X after 2 months of treatment
Because Coq9 X/X mice develop mitochondrial encephalopathy [9] , we evaluated the effects of the therapies on mitochondrial CoQ levels and mitochondrial respiratory chain function in cerebrum of the mutant mice. Mitochondrial CoQ 10 levels were significantly increased only after ubiquinol-10 treatment in Coq9 X/X mice, while vehicle or ubiquinone-10 supplementation did not increase the mitochondrial CoQ 10 levels ( Fig. 2A) . Considering the total mitochondrial CoQ pool (CoQ 9 + CoQ 10 ), ubiquinol-10 treatment increased mitochondrial CoQ levels ( Fig. 2B ) and decreased the CoQ 9 /CoQ 10 ratio after ubiquinol-10 treatment (Fig. 2C ).
3.3. CoQ-dependent mitochondrial respiratory chain activities and supercomplex pattern in cerebral mitochondria of Coq9 X/X after 2 months of treatment
Cerebral mitochondria of Coq9 X/X mice treated with vehicle showed a significant decrease of CI + III and CII + III activities compared to those of Coq9 +/+ mice ( Fig. 2D and E) . Similarly to the Pdss2 kd/kd mice, the decrease in CI + III activity was higher than the decrease in CII + III activity [14] . The increase of CoQ 10 levels in cerebral mitochondria of 
Coq9
X/X mice after ubiquinol-10 treatment induced a significant increase of CI + III activity (Fig. 2D ) and the normalization of CII + III activity (Fig. 2E) . On the contrary, vehicle or ubiquinone-10 treatments did not change the CoQ-dependent respiratory chain activities ( Fig. 2D and E) . The increase of the CoQ-dependent mitochondrial respiratory chain activities after ubiquinol-10 treatment was not due to an increase in the supercomplex I/III formation because the ratio supercomplex I/III/free complex III remained low in Coq9 X/X mice after vehicle, ubiquinone-10 or ubiquinol-10 treatment compared to Coq9 +/+ mice (Fig. 3A , B and C). The ratio supercomplex I/III/free complex I (Fig. S3A) , as well as complex I in gel activity, was similar in Coq9 +/+ mice and Coq9 X/X mice (Fig. S3B) , while the treatments did not produce any changes on these variables (Fig. S3) .
Histopathological evaluation and oxidative damage in brain of Coq9
X/X after 2 months of treatment Coq9 X/X mice show white matter vacuolization, severe reactive astrogliosis, reduction in neuronal dendrites and increased DNA oxidation, which were especially evident in diencephalon and brainstem [9] . The treatment with vehicle did not produce any change in these histopathological biomarkers because Coq9 X/X animals similarly showed white matter vacuolization ( Fig. 4C and D) and proliferation of astrocytes ( Fig. 4K and L) in diencephalon, as well as increased DNA oxidation in diencephalon and septum-striatum (Fig. 5C , D, K and L) compared to Coq9 +/+ mice (Fig. 4A , B, I and J; Fig. 5A , B, I and J). Treatment with ubiquinone-10 did not reduce the vacuolization (Fig. 4E and F) and astrogliosis ( Fig. 4M and N) in diencephalon of Coq9 X/X mice, while the immunoreactivity against 8-OHdG was slightly decreased in both diencephalon ( Fig. 5E and F) and septum-striatum ( Fig. 5M and N) . On the contrary, treatment with ubiquinol-10 was able to reduce the vacuolization ( Fig. 4G and H) and astrogliosis ( Fig. 4O and P) in diencephalon, as well as the DNA oxidation in both diencephalon ( Fig. 5G and H ) and septum-striatum ( Fig. 5O and P) . In brainstem, however, both ubiquinone-10 and ubiquinol-10 treatments were able to reduce the astrogliosis and DNA oxidation, as well as increase neuronal immunoreactivity (Figs. S4 and S5) . Nevertheless, the vacuolization still persisted with both treatments (Figs. S4 and S5 ). The histology structure of kidneys, muscle and heart was similar in all experimental groups (Fig. S6) .
Consequences of the treatments in the animal weight
Coq9 X/X mice show a reduction in the body weight between the age of 1 and 5 months [9] . Oral supplementation with vehicle or ubiquinone-10 did not produce any significant effect in body weight. On the contrary, ubiquinol-10 treatment significantly increased the body weight in both male (Fig. 6A ) and female ( Fig. 6B ) Coq9 X/X mice after two months of treatment, compared to Coq9 X/X mice treated with vehicle (Movie S1).
Discussion
Therapy based on oral supplementation with ubiquinone-10 has shown contradictory results in the treatment of primary and secondary CoQ 10 deficiencies, mitochondrial diseases and other neurological diseases like Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis or Huntington's Disease [2] [3] [4] [5] [6] [7] . These controversial results may be due to the poor absorption and bioavailability of ubiquinone-10 [7, 10, 15] . In this study, we demonstrate that a water-soluble formulation of ubiquinol-10, the reduced form of CoQ 10 , was more effective than that of ubiquinone-10 in increasing the levels of CoQ 10 in tissue homogenates and cerebral mitochondria, resulting in an increase of CoQ-dependent respiratory chain activities in the cerebrum of a CoQ deficient mouse model with mitochondrial encephalopathy (Coq9 X/X mice). As a consequence, ubiquinol-10 was more efficient than ubiquinone-10 in reducing the vacuolization, astrogliosis and oxidative damage in Coq9 X/X mice, thus increasing the animal body weight. Ubiquinone-10 in its pure form is a powder product that is insoluble in water and has partial solubility in lipids and organic solutions, and therefore it is poorly absorbed. The uptake of ubiquinone-10 is very low in brain because of the blood brain barrier. Moreover, the limitation of the exogenous ubiquinone-10 to reach mitochondria is one of the major problems for the CoQ 10 therapy because external ubiquinone-10 is distributed mainly in lysosomes and only a small amount, if any, is found in mitochondria [10, 15] . To try to increase the absorption of ubiquinone-10, different ubiquinone-10 formulations have been manufactured and are currently available on the market. These formulations include powder-based compressed tablets, chewable tablets, powder-filled hard-shell capsules, softgels containing an oil suspension and water-soluble formulations in softgel or liquid forms [8] . The latter forms are based in the ability of dextrins to increase the solubility of poorly water-soluble compounds with no toxic effects [16] . Our study shows that water-soluble formulation of ubiquinone-10 in a dose of 240 mg/kg bw/day, which is equivalent to 30 mg/kg bw/day in humans [17, 18] according to the body surface area [19] , is able to increase CoQ 10 levels in plasma of Coq9 X/X mice. The increase of plasma CoQ 10 concentration in Coq9 X/X mice was reflected in an increase of CoQ 10 levels in tissues of treated mice. The lowest increase of CoQ 10 in cerebrum and cerebellum may be due to the blood brain barrier. The highest increase of CoQ 10 in the liver may be explained by its mechanism of absorption in the gastrointestinal system. After gastric emptying, CoQ 10 is absorbed along with other lipids as chylomicron particles in the small intestine, and transported via lymph vessels to blood circulatory system and then taken up by the liver cells. In the liver, CoQ 10 is incorporated with lipoproteins and released into the blood, which is used as a transport vehicle to deliver CoQ 10 in other tissues [20, 21] . In another study, using ubiquinone-10 in oil suspension (LiQsorb, Tishcon) in doses of 200 and 400 mg/kg bw/day for 3-4 months, the authors did not find any increase of CoQ 10 in kidneys of a mouse model of CoQ deficiency due to Pdss2 mutation (Pdss2 kd/kd ) [22] . Similarly, the water-soluble formulation of ubiquinone-10 used in our study did not show a significant increase in the levels of CoQ 10 in kidney, suggesting that the vehicle does not affect the absorption of ubiquinone-10 at tissue level.
Our study also shows that ubiquinol-10 has better absorption, bioavailability and tissue uptake than ubiquinone-10 [23, 24] . Importantly, the increase of CoQ 10 after ubiquinol-10 treatment is not limited to tissue levels because CoQ 10 is also increased in mitochondria from the cerebrum of Coq9 X/X mice. As a consequence, ubiquinol-10 supplementation was able to increase the CoQ-dependent mitochondrial respiratory chain mice treated with ubiquinol-10 was still half of the activity in Coq9 +/+ mice. This result may be explained by the fact that ubiquinol-10 treatment was not able to normalize the supercomplex/ free CIII ratio (Fig. 3A ) [9] , and this may be justified by two possibilities: a) the accumulation of 5-demethoxyubiquinone-9 in Coq9 X/X mice, which was not corrected by the treatments, could partially inhibit the transfer of electrons from CI to CoQ, as it has been reported in Caenorhabditis elegans mutant clk-1 (analog to Coq7 in human and mouse) [25] ; and b) the increase of total CoQ (CoQ 9 + CoQ 10 ) after ubiquinol-10 treatment did not reach the required total CoQ levels in the Q binding sites of CI and CIII. Humans and mice have two CoQ forms, CoQ 9 and CoQ 10 , which differ with each other in the length size of the polyprenyl tail. While the reason to synthesize two CoQ forms is not clear and the same functions are attributed indistinctly to the two forms, an adequate CoQ 9 /CoQ 10 ratio may be necessary for an optimal performance of mitochondrial bioenergetics, including a physiological proportion of CIII free and CIII bound to supercomplexes. In fact, each tissue has a particular value on CoQ 9 /CoQ 10 ratio, with cerebrum and cerebellum being the tissues with lowest CoQ 9 /CoQ 10 ratio in mouse (highest in human) [26] . This fact points out that CoQ 9 /CoQ 10 ratio seems to be tightly regulated in a tissue specific way. In Coq9 X/X mice, a decrease in CoQ 9 /CoQ 10 ratio was detected in cerebrum and cerebellum homogenates, as well as in isolated mitochondria from cerebrum (Figs. S1 and 2C), and the ratio was even lower after ubiquinol-10 treatment (Figs. S1 and 2C). Future therapeutic strategies focused in increasing the endogenous CoQ 9 and CoQ 10 biosynthesis could contribute to understand the importance of CoQ 9 in mitochondrial bioenergetics. In addition to its bioenergetics role, CoQ 10 is one of the most important endogenous antioxidants in the cell [1] . CoQ 10 deficiency is accompanied with an increased production of reactive oxygen species (ROS) and oxidative damage to biomolecules, which leads to an increased cell death in vitro [27, 28] and in vivo [14] . Coq9 X/X mice also show an increase of 8-OHdG in diencephalon, septum-striatum and brainstem, [9] (Figs. 5 and 4s). Both ubiquinone-10 and ubiquinol-10 reduced the immunostaining against 8-OHdG, but the reduction was higher with ubiquinol-10. This result may reflect the higher uptake of ubiquinol-10 compared to ubiquinone-10, its higher antioxidant capacity and/or an effect in reducing the leak of electrons through the mitochondrial respiratory chain. Following the biochemical changes after the treatments, supplementation with ubiquinol-10 reduced the vacuolization and astrogliosis in diencephalon, septum-striatum and, to a lesser extent, in brainstem of Coq9 X/X mice. The lower efficiency of ubiquinol-10 treatment in reducing the histopathological changes in brainstem of Coq9 X/X mice compared to diencephalon and septum-striatum may be related to an early and irreversible damage in this area, which is particularly susceptible in Leigh syndrome [29, 30] . Notably, ubiquinol-10 was more powerful than ubiquinone-10 in reducing the histopathological changes in Coq9 X/X mice, resulting in an increase in the body weight. These results are particularly important because patients with CoQ 10 deficiency showed variable responses to ubiquinone-10 treatment and, in some cases, the treatment failed or did not show a clear response [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] , which may be due to the reduced uptake of ubiquinone-10 [7] . Thus, our results suggest that ubiquinol-10 supplementation could improve the efficacy showed by ubiquinone-10 supplementation, which will be especially important in patients with encephalopathy or cerebellar ataxia associated to CoQ 10 deficiency. In agreement with that, in a patient with CoQ 10 deficiency, mental retardation, encephalomyopathy and dimorphic features due to a COQ4 mutation, ubiquinol-10 in a dose of 15 mg/kg bw/day had the same efficiency than ubiquinone-10 in a dose of 30 mg/kg bw/day [18] .
Conclusions
Our results demonstrate that dextrin-based water-soluble formulations of ubiquinol-10 have better absorption and uptake at tissue and mitochondrial levels, which results in an increase of CoQ-dependent respiratory chain activities, reduction in vacuolization, astrogliosis and oxidative damage in different brain areas, and an increase of body weight in a CoQ deficient mouse model with mitochondrial encephalopathy. This data suggest that water-soluble formulations of ubiquinol-10 should be preferentially used for CoQ 10 therapy. However, ubiquinol-10 supplementation did not completely rescue the encephalopathic phenotype of the Coq9 X/X mouse model. Considering that mice and humans produce both CoQ 9 and CoQ 10 , future therapeutic strategies focused in increasing both CoQ 9 and CoQ 10 levels could lead to obtain better results. Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.bbadis.2014.02.008. 
